by Raynovich Rod | Aug 23, 2018 | 2024-25 Life Science Portfolios, Biopharmaceuticals, Clinical Diagnostics and Tools
8/24/18 After Close: Rally Continues with 10/11 Sectors Higher XLV finishes at all time high at $91.89 FED’s Powell Defends Gradual Interest Rate Policy despite Trump pressure Oil Surges 15 to $68.57 on supply concerns with Iran sanctions Major indices hit 52...
by Raynovich Rod | Jun 19, 2018 | Biopharmaceuticals, Clinical Diagnostics and Tools
Rayno Life Science Portfolio FMI: Personalized Medicine for Oncology We are on vacation this week but need to update you on Roche (RHHBY) complete buyout of Foundation Medicine (FMI) one of our top picks in personalized medicine for oncology. FMI is up 28% to $136.50...
by Raynovich Rod | Jun 6, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
ASCO 2018 Biotech Rally: Biotechs, Techs, and Semis Lead Market Higher Mid-Caps show huge gains but with high volatility. FBT at 142.91, IBB lagging at $110.52, XBI leading at $97.77 IWC Micro-Cap ETF breaking out up 11% YTD. Healthcare (XLV) comes to life lately up...
by Raynovich Rod | Jan 11, 2018 | Clinical Diagnostics and Tools
Key Trends in Diagnostics and Lifesciences: Promise, Reality Reimbursement Panel Moderator: Ken Bahk, Three Lake Partners. Panelists- Nathan Ledeboer, Medical College of Wisconsin,Victoria Pratt, Indiana University School of Medicine, Nick Papadopolous, Johns Hopkins...
by Raynovich Rod | Jan 9, 2018 | Clinical Diagnostics and Tools
2018 Digital Health Panel: Is Digital Health at an Inflection Point? A packed session in the Colonial Room at the J.P.Morgan Healthcare Conference heard a panel of scientists, investors and entrepreneurs moderated by Lloyd B.Minor M.D., Dean, Carl and Elizabeth...
by Raynovich Rod | Dec 20, 2017 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Clinical Diagnostics and Tools: Big Winners Are In Genomics and Personalized Medicine Slower growth in routine clinical diagnostics, tools are favored. Hologic has a unique business model for women’s health and diagnostics. Gene sequencing is important for...
by Raynovich Rod | Sep 27, 2017 | Clinical Diagnostics and Tools
Life Science Tools and Services Stocks Have Outperformed Biopharmaceuticals With Less Volatility Large Caps Are Winners in 2017 We have not covered the Life Science Tools and Diagnostics sector since early 2016 when life science stocks abruptly sold off. We have...
by Raynovich Rod | Aug 7, 2017 | 2024-25 Life Science Portfolios, Clinical Diagnostics and Tools
8/10 Red Screen in the Morning We cautioned on XBI at $78 on 7/31 and today it broke through support at $75 to $74.70. ======= 8/9 Update After Close: A Bit of Caution after Trump’s “Fire and Fury” Talk Investors are holding off as global risks rise...
by Raynovich Rod | Jun 27, 2017 | Biopharmaceuticals, Clinical Diagnostics and Tools
Genomics and the Future of Personalized Medicine and Diagnostics Description of Track The opening plenary of the Personalized Medicine & Diagnostics Track will feature J. Craig Venter, Founder, Chairman and Chief Executive Officer of the J. Craig Venter Institute,...
by Raynovich Rod | Jun 26, 2017 | Biopharmaceuticals, Clinical Diagnostics and Tools
Big Data Provides Pathway to Precision Medicine Description of Track Speaker Atul Butte, MD,Ph.D. Director, UCSF Institute for Computational Health Sciences The remarkable ascent of Big Data for example from biomedical imaging, next generation sequencing and adjacent...
